Mayne Pharma nears deal for Teva assets: source

(Reuters) – Australia’s Mayne Pharma Group Ltd on Tuesday said it will acquire U.S. generic products from Teva Pharmaceuticals for $652 million, helping it propel into the top 2 in the general oral…

Leave a Reply

Read the original at Reuters: Deals.